Monthly for the first three months during titration, then quarterly once you reach a stable maintenance dose
GLP-1s have been shown to aid in weight reduction in obese patients with and without diabetes through improved glycemic control via stimulating insulin and inhibiting glucagon
2017: The FDA approves a long-acting, once weekly GLP-1 RA injectable exenatide (Bydureon BCise)
In the safety profile, pooling three studies with 640 patients, most adverse events associated with retatrutide were mild and did not result in treatment discontinuation
We performed a students paired t-test to determine statistically significant changes in the levels of the components of metabolic syndrome, lipid panel, hepatic panel, and adiposity, oxidative stress, and inflammation biomarkers measured at the end of 4th week during 4-week intermittent fasting, and 1 week after 4-week intermittent fasting
The PlexusDx Precision Peptide Genetic Test ($99) reveals your genetic predisposition across 14 metabolic pathways, including GLP1R and GIP receptor variants that influence medication responsiveness
